Clinical Research Division
- Adair Lab
Develops new gene therapy treatments and protocols for the treatment of many different genetic and infectious diseases
- AML Treatment Tools
Dr. Mohammed Sorror at Fred Hutch is working to develop assessment tools to better predict the survival after bone marrow transplant for patients with acute myeloid leukemia
- Bedalov Lab
The Bedalov Lab conducts research to identify drugs that disrupt gene silencing, a process that has been implicated in cancer and other diseases in which genes are inappropriately shut off.
- Bernstein Lab
Dr. Irwin D. Bernstein's research interests include normal and leukemic hematopoietic stem cells, antibody targeted therapies for lymphoma and leukemia, and the biology of acute myeloid leukemia.
- Bezos Family Immunotherapy Clinic
The Bezos Family Immunotherapy Clinic, named in recognition of a family that has been deeply committed to the Hutch and its work to advance immunotherapy, will allow researchers to conduct twice as many immunotherapy trials in the next year in pursuit of speeding cures for cancer.
- Biobehavioral Sciences
The Biobehavioral Sciences program investigates mechanisms and methods for integrating behavioral and biological components of care for cancer survivors during and following active treatment.
- Bleakley Lab
Strategies to engineer hematopoietic stem cell grafts to prevent GVHD and augment graft-versus-leukemia in order to prevent relapse, adoptive T cell immunotherapy to augment graft-versus-leukemia and histocompatibility antigens as targets for future immunotherapy, graft engineering to manage relapse after transplant.
- Cancer Immunotherapy Trials Network
CITN employs the expertise of top academic immunologists to design and conduct early phase clinical trials with the most promising immunotherapy agents.
- Chapuis Lab
Focused on understanding the factors associated with successful therapies so that adoptive T cell therapies can be further optimized to better eliminate tumors.
- Clinical Biostatistics
Clinical Biostatistics researchers collaborate in numerous inter-disciplinary projects across Fred Hutch and the Consortium. Their work contributes to Fred Hutch’s goal of translating discoveries into cures.
- Clurman Lab
The Clurman Lab studies how cell division is regulated in normal cells, and how abnormal control of cell division leads to cancer. They hope to use these mechanistic insights into tumor formation to develop new cancer treatment strategies.
- Cord Blood Program
The cord blood program is using a method we developed to multiply (“expand”) cord blood cells, we are creating opportunities for using these cells as a bridge therapy of infection-fighting cells to improve patients’ transplant survival and reduce infection risk during chemotherapy.
- Delaney Lab
The focus of the Delaney Lab is the development and clinical translation of methodologies for the ex vivo expansion of hematopoietic stem and progenitor cells. In particular, cord blood stem and progenitor cells with the goal of improving outcomes for patients undergoing cord blood transplantation.
- Dey Lab
The Dey lab studies how the gut microbiome influences physiology and pathophysiology in health and disease.
- Dudakov Lab
The focus of the Dudakov lab is to elucidate the mechanisms underlying endogenous thymic regeneration so that they may be exploited into therapeutic strategies to boost immune function.
- Grady Lab
The Grady lab research is ocused on the role of epigenetic alterations as risk markers and biomarkers for esophageal and colon cancer, respectively and of the role of genetic and epigenetic alterations in carcinogenesis.
- Green Lab
The Green lab is investigating new immunotherapy based approaches to treat multiple myeloma (MM) and lymphoma. Ideally, a tumor target (antigen) should be expressed homogeneously on the cancer cell’s surface and not be found on normal tissue.
- Greenberg Lab
Research is focused on the immunobiology of viral and malignant diseases, and developing cellular and molecular strategies to manipulate T cell immunity for the treatment of human diseases.
- GVHD Assessment Video
- Hadland Lab
The Hadland lab’s focus is in understanding the origin of blood and immune cells during development. We are particularly interested in determining the mechanisms by which hematopoietic stem cells (HSC) arise and how they acquire their unique properties, such as the capacity for life-long self-renewal and multilineage hematopoietic reconstitution following transplantation.
- Headley Lab
The goal of the Headley Lab is to understand how dynamic interactions at the level of individual cells influence disease. The lab currently is focused on understanding how cells of the immune system participate in the process of lung metastasis of cancer (the spread of tumor cells from primary cancer sites to the lung).
- Heimfeld Lab
The Heimfeld Lab focuses on the translation of new cell-based therapies from the scientist's bench to the patient's bedside. Areas of research include improvements in specific cell-subset selection, large-scale therapeutic-cell culturing in closed systems, optimized cryopreservation and cell storage.
- Hingorani Lab
Investigates the molecular and cellular mechanisms that drive the pathogenesis of pancreatic ductal adenocarcinoma (PDA) or, more commonly, pancreas cancer.
- Immunology Study
Fred Hutch is recruiting volunteers for a study focused on the development of new immunotherapy-based treatment. Study volunteers will go through a screening process to determine eligibility. Eligible donors are added to our database for study enrollment. Eligible donors will be invited to attend a blood draw donation event.
- Institute for Prostate Cancer Research (IPCR)
The institute is a collaborative effort of Fred Hutchinson Cancer Research Center and UW Medicine. A natural outgrowth of established research and clinical collaborations, the IPCR brings together a world-renowned team whose mission is to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics and improve survival and quality of life.
- J. Lee Nelson Lab
The J. Lee Nelson Lab studies microchimerism, a natural state in which cells are exchanged between mother and fetus during pregnancy and can remain in the other individual decades later. They study the role of this phenomenon in autoimmune diseases, pregnancy complications and cancer, as well as its impact on the success of blood stem-cell and organ transplants.
- Kiem Lab
The Kiem Lab studies stem cell biology and stem cell gene transfer with the goal of developing new treatment strategies for patients with genetic and infectious diseases and cancers.
- Lee Lab
Our work focuses on hematopoietic stem cell transplant patients and chronic graft-versus-host disease (cGHVD). Dr. Lee is the lead investigator and Fred Hutchinson Cancer Research Center is the coordinating center for the Chronic Graft-versus-Host Disease Consortium within the Rare Diseases Clinical Research Network.
- Long-Term Follow-Up
- Lymphoma Program
- Mendez Lab
Our research is looking to discover which genes are related specifically to the spread of head and neck cancers to other parts of the body by comparing the genetics of tumors that have not spread with those that have. We hope to one day allow physicians to predict which tumors are more likely to spread, information that will, in turn, affect treatment decisions.
- Oehler Lab
Research and clinical focuses on the mechanisms of leukemia disease initiation/progression and therapy resistance, new agents in the treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), including myeloproliferative and myelodysplastic disorders.
- Olson Lab
The Olson Lab studies pediatric brain tumors, brain development and neurodegenerative disorders. The lab has a strong focus on emergent technologies such as "tumor paint," which causes cancer cells to glow with light so that surgeons can see them during an operation.
- Orozco Lab
Focus on developing and improving antibody therapies for leukemia and lymphoma patients, with the goal of translating laboratory findings into the clinic and increasing the effectiveness of radioimmunotherapy by developing “pre-targeted” methods for more selectively delivering radiation to tumor sites.
- Paulovich Lab
The Paulovich Lab works to characterize human variation and to relate this variation to clinically relevant endpoints, such as predicting a patient's risk of cancer and tolerance for treatments. Projects range from studying cellular DNA damage response in yeast and mammalian cells, to developing novel mass spectrometry-based technologies for finding and validating new protein biomarkers to serve as diagnostic tests.
- Pollack Lab
The Pollack Lab is developing new ways to culture and engineer T cells with sarcoma specificity and learning how to overcome the inhibitory effects of the sarcoma tumor microenvironments on what might otherwise be effective immunotherapies
- Press Lab
Dr. Press is a pioneer in immunotherapy, a treatment strategy that harnesses the power of the immune system. His lab engineers antibodies that help to destroy cells involved in blood cancers and carry radiation directly to cancer cells. They also genetically modify disease-fighting T-cells to boost their ability to recognize and kill lymphoma cells.
- Program in Immunology
The Program in Immunology is focused on learning how immune cells respond to disease and how to safely enhance immunity to better control, cure and potentially prevent malignancies and many other serious conditions.
- Radich Lab
The Radich Lab studies the molecular genetics of response, progression and relapse in human leukemia. Research topics include the detection of minimal residual disease, the role of signal transduction abnormalities in leukemia, and the construction of gene-expression profiles of response and progression.
- Research Cell Bank
The Research Cell Bank (RCB) is a qualified, experienced research facility that has been actively engaged in clinical research through B-lymphoblastoid cell (B-LCL) transformation and maintenance, DNA extraction, and inventory control for more than 30 years. The RCB is currently expanding its role as a core repository of reagents and services to better serve the needs of investigators worldwide.
- Riddell Lab
Elucidating how T cells recognize cancer cells and pathogens and how to safely enhance T cell immunity to better control, cure and potentially prevent malignancies and serious viral infections.
- Rongvaux Lab
The Rongvaux Lab studies the innate immune response, the very first steps in the development of the immune response, after exposure to a pathogen or formation of a tumor.
- Shadman Group
The Shadman Group's research focuses on studying epidemiology of hematologic neoplasms; and the association between autoimmune disorders, allergy and asthma and hematologic malignancies.
- Simon Lab
Research is focused on the development of new anticancer drugs through a wide range of experimental techniques and systems, ranging from organic synthesis to genetic screens. The compounds being studied have been identified from large collections of synthetic, drug-like compounds and from natural sources.
- Spot on CML
Fred Hutch's Radich lab devised a low-cost, paper-based method to diagnose chronic myeloid leukemia (CML) and is working with the Max Foundation to make this tool available in low- and middle-income countries.
- Stephan Lab
Research focused on gastrointestinal cancer prevention, including genetic and clinical predisposition, chemoprevention, and early detection.
- Stirewalt Lab
The Stirewalt Lab is using AML as a prototype to explore the relationship of aging and malignant transformation, and how aging may be changing the biology of the hematopoietic diseases in older adults.
- Storb Lab
Transplantation Biology combines basic and translational research directed at understanding and eliminating major barriers to successful allogeneic hematopoietic stem cell transplantation; these include host-versus-graft reactions, graft failure, acute and chronic graft-versus-host disease (GVHD), regimen-related toxicities, and induction of graft-versus-tumor reactions. The program’s goal has been to use stem cell transplantation to treat patients with malignant and nonmalignant hematologic diseases.
- Survivorship Program
Fred Hutchinson Cancer Research Center's Survivorship Program offers support, treatment and education to cancer survivors.
A member of the LIVESTRONG Survivorship Center of Excellence Network, the Survivorship Program is helping to lead a nationwide effort to help survivors and their healthcare providers understand, prevent and manage the medical and psychosocial effects of having cancer and receiving treatment.
- Till Lab
Translational research on chimeric antigen receptor (CAR) T cells and assessing the function of CAR T cells targeting CD20 and CD19 in vitro and in mouse models, including correlative assays investigating the development of endogenous anti-tumor immune responses following CAR T cell therapy
- Turtle Lab
The Turtle Laboratory in the Fred Hutch Program in Immunology is focused on understanding the characteristics of distinct subsets of human T cell subsets, their potential utility for tumor immunotherapy and their role in immune reconstitution after HCT.
- Walter Lab
Research is focused on clinical trials testing new drugs and drug combinations to treat acute myeloid leukemia.
- Warren Lab
The Warren Lab studies human antitumor immune responses at the cellular and molecular level in order to learn how these immune responses can be exploited to treat human cancer.